



Figure S1. Dot plot of propensity-score matching.

βB: beta-blocker; CRT: cardiac resynchronization therapy; HFrEF: heart failure with reduced ejection fraction; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; RASi: renin-angiotensin system inhibitor.

Table S1. Main baseline characteristics of the study population after propensity-score matching.

Parameters	PSM total cohort (<i>n</i> = 168)	PSM HFOC (<i>n</i> = 84)	PSM non-HFOC (<i>n</i> = 84)	<i>p</i> -Value
Male gender, <i>n</i> (%)	132 (79)	65 (77)	67 (80)	0.851
Age, median [IQR], years	63 [50-69]	64 [52-70]	62 [48-68]	0.623
Previous hospitalization primarily due to heart failure, <i>n</i> (%)	70 (42)	37 (44)	33 (39)	0.639
De novo HfrEF, <i>n</i> (%)	48 (29)	23 (27)	25 (30)	0.865
Ischemic etiology, <i>n</i> (%)	74 (44)	37 (44)	37 (44)	1.000
LVEF, median [IQR], %	25 [20-30]	25 [20-30]	25 [19-30]	0.611
Heart rate, median [IQR], min ⁻¹	87 [71-100]	85 [70-100]	88 [73-100]	0.495
Systolic blood pressure, median [IQR], mmHg	118 [102-137]	117 [102-137]	120 [103-135]	0.586
Distance from HFOC, median [IQR], km	11 [5-67]	13 [5-73]	8 [6-54]	0.578
Comorbidities				
Diabetes, <i>n</i> (%)	66 (39)	35 (42)	31 (37)	0.636
Hypertension, <i>n</i> (%)	107 (64)	53 (63)	54 (64)	1.000
Atrial fibrillation/flutter, <i>n</i> (%)	69 (41)	36 (43)	33 (38)	0.754
Laboratory parameters at hospital discharge				
creatinine, median [IQR], μmol/L	111 [85-147]	112 [86-155]	106 [83-145]	0.499
eGFR, median [IQR], mL/min/1.73m ²	61 [39-83]	58 [38-79]	63 [42-86]	0.423
potassium, median [IQR], mmol/L	4.4 [4.1-4.7]	4.4 [4.1-4.7]	4.4 [4.1-4.7]	0.975
hemoglobin, median [IQR], g/L	122 [108-138]	124 [108-139]	121 [106-138]	0.685
Medical and device therapy at hospital discharge				
RASi, <i>n</i> (%)	153 (91)	78 (93)	75 (89)	0.590
ACEi/ARB, <i>n</i> (%)	123 (73)	58 (69)	65 (77)	0.296
ARNI, <i>n</i> (%)	30 (18)	20 (24)	10 (12)	0.069
βB, <i>n</i> (%)	149 (89)	74 (88)	75 (89)	1.000
MRA, <i>n</i> (%)	160 (95)	81 (96)	79 (94)	0.720
Triple therapy, <i>n</i> (%)	136 (81)	68 (81)	68 (81)	1.000
SGLT2i, <i>n</i> (%)	21 (13)	12 (14)	9 (11)	0.642
TD RASi, <i>n</i> (%)	43 (26)	19 (23)	24 (29)	0.480
TD ACEi/ARB, <i>n</i> (%)	37 (22)	16 (19)	21 (25)	0.457
TD ARNI, <i>n</i> (%)	6 (4)	3 (4)	3 (4)	1.000
TD βB, <i>n</i> (%)	36 (21)	23 (27)	13 (15)	0.090
TD MRA, <i>n</i> (%)	120 (71)	58 (69)	62 (74)	0.609
TD Triple therapy, <i>n</i> (%)	11 (7)	5 (6)	6 (7)	1.000
CRT-P/CRT-D, <i>n</i> (%)	27 (16)	14 (17)	13 (15)	1.000
ICD, <i>n</i> (%)	48 (29)	27 (32)	21 (25)	0.393

ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor neprilysin inhibitor; βB: beta-blocker; CRT-P/CRT-D: cardiac resynchronization therapy pacemaker/defibrillator; eGFR: estimated glomerular filtration rate; HFOC: heart failure outpatient care; HfrEF: heart failure with reduced ejection fraction; ICD: implantable cardioverter defibrillator; [IQR]: interquartile range; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; PSM: propensity-score matching; RASi: renin-angiotensin system inhibitor; SGLT2i: sodium-glucose cotransporter 2 inhibitor; TD: target dose.

Table S2. Medical and device therapy at 1 year in the total cohort and after propensity-score matching.

	Total cohort (<i>n</i> = 191)	HFOC (<i>n</i> = 95)	non-HFOC (<i>n</i> = 96)	<i>p</i> -Value	PSM total cohort (<i>n</i> = 125)	PSM HFOC (<i>n</i> = 67)	PSM non- HFOC (<i>n</i> = 58)	<i>p</i> -Value
RASi, <i>n</i> (%)	163 (85)	89 (94)	75 (78)	0.007	110 (88)	64 (96)	46 (79)	0.011
ACEi/ARB, <i>n</i> (%)	118 (61)	55 (58)	64 (67)	0.182	81 (65)	43 (64)	38 (65)	1.000
ARNI, <i>n</i> (%)	45 (24)	34 (36)	11 (11)	<0.001	29 (23)	21 (32)	8 (14)	0.033
βB, <i>n</i> (%)	170 (89)	89 (94)	81 (84)	0.062	114 (91)	64 (96)	50 (86)	0.111
MRA, <i>n</i> (%)	158 (83)	90 (95)	68 (71)	<0.001	108 (86)	65 (97)	43 (74)	<0.001
Triple therapy, <i>n</i> (%)	139 (73)	84 (88)	55 (57)	<0.001	99 (79)	61 (91)	38 (66)	<0.001
SGLT2i, <i>n</i> (%)	25 (13)	17 (18)	8 (8)	0.056	17 (14)	11 (16)	6 (10)	0.434
TD RASi, <i>n</i> (%)	80 (42)	46 (48)	34 (35)	0.079	54 (43)	33 (49)	21 (36)	0.153
TD ACEi/ARB, <i>n</i> (%)	59 (31)	30 (31)	29 (30)	0.876	41 (33)	24 (36)	17 (29)	0.453
TD ARNI, <i>n</i> (%)	21 (11)	16 (17)	5 (5)	0.011	13 (10)	9 (13)	4 (7)	0.258
TD βB, <i>n</i> (%)	69 (36)	51 (54)	18 (19)	<0.001	47 (38)	34 (51)	13 (22)	0.002
TD MRA, <i>n</i> (%)	111 (58)	63 (66)	48 (50)	0.028	81 (65)	47 (70)	34 (59)	0.194
TD Triple therapy, <i>n</i> (%)	31 (16)	23 (24)	8 (8)	0.003	22 (18)	15 (22)	7 (12)	0.161
CRT-P/CRT-D, <i>n</i> (%)	39 (20)	30 (32)	9 (9)	<0.001	18 (14)	11 (16)	7 (12)	0.612
ICD, <i>n</i> (%)	44 (23)	27 (28)	17 (18)	0.088	36 (29)	23 (34)	13 (22)	0.168

ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor neprilysin inhibitor; βB: beta-blocker; CRT-P/CRT-D: cardiac resynchronization therapy pacemaker/defibrillator; eGFR: estimated glomerular filtration rate; HFOC: heart failure outpatient care; ICD: implantable cardioverter defibrillator; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; PSM: propensity-score matching; RASi: renin-angiotensin system inhibitor; SGLT2i: sodium-glucose cotransporter 2 inhibitor; TD: target dose.

Table S3. Predictors of 1-year all-cause mortality and 1-year all-cause rehospitalization using univariate Cox regression analysis.

1-year all-cause mortality				
	HR	95% CI		p-Value
Age (/1 year)	1.058	1.034	1.083	<0.001
Female gender	1.084	0.600	1.959	0.789
Heart rate (/1 min ⁻¹)	0.992	0.980	1.004	0.215
Systolic blood pressure (/1 mmHg)	0.983	0.971	0.996	0.012
eGFR at discharge (/1 mL/min/1.73 m²)	0.975	0.963	0.987	<0.001
Potassium at admission > 4.5 mmol/L	1.068	0.632	1.805	0.807
Left ventricular ejection fraction (/1%)	0.991	0.953	1.030	0.648
Diabetes	1.721	1.019	2.908	0.042
Hypertension	1.485	0.832	2.653	0.181
Atrial fibrillation/flutter	1.986	1.162	3.397	0.012
Coronary artery disease	0.976	0.577	1.650	0.928
CRT at discharge	1.101	0.570	2.219	0.775
HFOC	0.412	0.228	0.744	0.003
Triple therapy at discharge	0.286	0.169	0.484	<0.001
1-year all-cause rehospitalization				
	HR	95% CI		p-Value
Age (/1 year)	1.025	1.009	1.041	0.002
Female gender	0.677	0.409	1.118	0.127
Heart rate (/1 min ⁻¹)	1.001	0.992	1.009	0.899
Systolic blood pressure (/1 mmHg)	0.999	0.990	1.008	0.784
eGFR at discharge (/1 mL/min/1.73 m²)	0.988	0.979	0.998	0.013
Potassium at discharge > 4.5 mmol/L	0.790	0.526	1.187	0.257
Left ventricular ejection fraction (/1%)	0.992	0.964	1.021	0.603
Diabetes	1.438	0.961	2.151	0.077
Hypertension	1.223	0.800	1.869	0.354
Atrial fibrillation/flutter	1.405	0.942	2.098	0.096
Coronary artery disease	1.347	0.902	2.011	0.146
CRT at discharge	0.840	0.484	1.457	0.534
HFOC	0.619	0.410	0.934	0.022
Triple therapy at discharge	0.463	0.300	0.715	0.001

CI: confidence interval; CRT: cardiac resynchronization therapy; eGFR: estimated glomerular filtration rate; HFOC: heart failure outpatient care; HR: hazard ratio. The predictors proven are marked as bold.